Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

OBJECTIVES: We investigated JNJ-64530440 (a hepatitis B virus capsid assembly modulator) safety, antiviral activity and pharmacokinetics in patients with chronic hepatitis B (CHB) (Phase 1b, NCT03439488). METHODS: Twenty treatment-naive, HBeAg-positive or -negative CHB patients were randomized 4‍:‍1...

Descripción completa

Detalles Bibliográficos
Autores principales: Gane, Ed J., Schwabe, Christian, Berliba, Elina, Tangkijvanich, Pisit, Jucov, Alina, Ghicavii, Nelea, Verbinnen, Thierry, Lenz, Oliver, Talloen, Willem, Kakuda, Thomas N., Westland, Chris, Patel, Megha, Yogaratnam, Jeysen Z., Dragone, Leonard, Van Remoortere, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969529/
https://www.ncbi.nlm.nih.gov/pubmed/35040959
http://dx.doi.org/10.1093/jac/dkab491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969529/
https://www.ncbi.nlm.nih.gov/pubmed/35040959
http://dx.doi.org/10.1093/jac/dkab491

Ejemplares similares